

Table S12. Effectiveness of anti-CTLA-4 monotherapy, anti-CTLA-4/anti-PD-1 combo, BRAFi/MEKi combo, and chemotherapy after failure of anti-PD-1 monotherapy (n=87)

Treatment	PFS (month)	CR	Best Response (%)		
	(95% CI)		PR	SD	PD
Anti-CTLA-4 monotherapy (for PFS, n=15; for response, n=14)	3 (2 to 13)	1 (7)	2 (14)	3 (21)	8 (57)
Anti-CTLA-4/Anti-PD-1 combo (for PFS, n=4; for response, n=3)	2 (0.3 to NR)	0	1 (33)	0	2 (67)
BRAFi/MEKi combo (for PFS, n=20; for response, n=18)	5 (4 to 12)	1 (6)	8 (44)	6 (33)	3 (17)
Rechallenge (for PFS, n=8; for response, n=7)	4 (3 to NR)	1 (14)	1 (14)	3 (43)	2 (29)
Naïve (for PFS, n=12; for response, n=11)	6 (4 to NR)	0	7 (64)	3 (27)	1 (9)
Chemo (for PFS, n=20; for response, n=21)	1 (1 to 4)	0	0	8 (38)	13 (62)

NR, not reached.